• United Therapeutics reported full Phase 3 ADVANCE OUTCOMES results for investigational ralinepag at the American Thoracic Society meeting in 2026.
• The study met its primary goal, showing ralinepag lowered the risk of clinical worsening in pulmonary arterial hypertension patients who were largely already on standard background therapy.
• Secondary results showed improvement in a key heart-failure biomarker and exercise capacity, supporting a broader efficacy profile without citing technical measurements.
• No new safety concerns emerged, with side effects consistent with the prostacyclin drug class.
• An FDA filing is planned for the second half of 2026, positioning ralinepag as a potential once-daily oral option if cleared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202605171415BIZWIRE_USPR_____20260517_BW812558) on May 17, 2026, and is solely responsible for the information contained therein.